• 60-fold greater efficacy than standard medication
• Results achieved in laboratory and animal studies
• 43 percent of the global population infected with H. pylori

A significant step toward the potential prevention of stomach cancer: Researchers at the Technical University of Munich (TUM) have increased the effectiveness of a standard antibiotic by a factor of 60 through targeted chemical modifications. In laboratory and animal studies, the new drug candidate successfully combats the bacterium Helicobacter pylori, which is closely associated with the development of stomach cancer. The study findings were published in the journal Nature Microbiology.